LP-911888 is an orally active ACSL5/ACSL1 inhibitor, with IC50 values of 1 nM and 3 nM against mouse and human ACSL5, and IC50 values of 2 nM and 9 nM against mouse and human ACSL1, respectively. LP-911888 inhibits intestinal triglyceride uptake; it also reduces body weight and food consumption in diet-induced obese mice, and delays gastric emptying by activating the ileal brake pathway. LP-911888 can be used in studies of diet-induced obesity [1].
In Vivo, LP-911888 (1-10 mg/kg; p.o.) dose-dependently inhibits intestinal triglyceride uptake. It also reduces body weight and food intake in diet-induced obese mice, and delays gastric emptying by activating the ileal brake pathway[1].
References:
[1]. Powell DR, et al. Acyl-CoA Synthetase 5 Knockout and Inhibitors Protect Against Diet-Induced Obesity in Mice by Activating the Ileal Brake. J Endocr Soc. 2025;10(2):bvaf196. Published 2025 Nov 28.
In Vivo, LP-911888 (1-10 mg/kg; p.o.) dose-dependently inhibits intestinal triglyceride uptake. It also reduces body weight and food intake in diet-induced obese mice, and delays gastric emptying by activating the ileal brake pathway[1].
References:
[1]. Powell DR, et al. Acyl-CoA Synthetase 5 Knockout and Inhibitors Protect Against Diet-Induced Obesity in Mice by Activating the Ileal Brake. J Endocr Soc. 2025;10(2):bvaf196. Published 2025 Nov 28.